Ipsen to Acquire Kartos Therapeutics for Myelofibrosis Drug

Ipsen Acquires Kartos Therapeutics for $450M Upfront to Boost Myelofibrosis Pipeline

French pharmaceutical company Ipsen is set to acquire California-based Kartos Therapeutics in a deal valued at $450 million upfront, with potential goal-based payments reaching up to $1.3 billion. The acquisition focuses on Kartos' experimental myelofibrosis drug, navtemadlin, an MDM2 blocker currently in Phase 3 testing for intermediate and high-risk myelofibrosis. This strategic move aims to bolster Ipsen's pipeline in rare blood cancers, with the acquisition expected to finalize in the third quarter.

• Ipsen is making a strategic acquisition of Kartos Therapeutics, significantly expanding its portfolio in rare blood cancers. The financial terms include an initial $450 million payment at closing, with potential milestone payments that could total up to $1.3 billion, contingent on regulatory approvals and sales performance. This substantial investment underscores Ipsen's commitment to late-stage assets with high market potential.
• The central asset in this acquisition is navtemadlin, Kartos' experimental drug targeting myelofibrosis, a rare and serious blood cancer. Navtemadlin is specifically being developed for intermediate and high-risk myelofibrosis patients, addressing a critical unmet need in this population. Its advanced stage in Phase 3 clinical trials positions it as a near-term potential therapeutic option for patients.
• Navtemadlin operates by blocking MDM2, a crucial regulator of the p53 protein, which is vital for tumor suppression. This targeted mechanism suggests a precise approach to treating myelofibrosis. The drug's progression to Phase 3 testing, supported by promising early data, indicates robust clinical development and a significant step towards potential market authorization, with the acquisition expected to close in the third quarter.

Ipsen's New Asset: Navtemadlin's Broader Therapeutic Scope

Navtemadlin's therapeutic potential extends well beyond myelofibrosis, with clinical and preclinical investigations spanning several oncologic and non-oncologic indications. The breadth of these programmes reflects the mechanistic versatility of MDM2 inhibition across TP53 wild-type disease contexts, with intervention models ranging from surgical window-of-opportunity designs to xenograft and patient-derived preclinical frameworks.

• Recurrent Glioblastoma (NCT03107780): A surgical window-of-opportunity trial enrolled 21 patients with TP53 wild-type recurrent GBM to evaluate achievable intratumoral drug concentrations and characterise mechanisms of response and resistance. Participants received navtemadlin at 120 mg (n=10) or 240 mg (n=11) for two days prior to surgical resection, then continued post-operatively until progression or unacceptable toxicity. Both dose levels achieved pharmacodynamic impact, though median progression-free survival was 3.1 months; combination with temozolomide was identified as a potential route to more durable benefit.

• EBV-Positive B-Cell Lymphomas: Navtemadlin demonstrated potent in vivo activity in preclinical xenograft models established in immunocompromised mice, with tumour regression observed across all five EBV-positive xenograft-associated B-cell lymphomas tested. Notably, navtemadlin prevented systemic dissemination of EBV-positive lymphoma derived from two juvenile posttransplant lymphoproliferative disease patients — including one whose tumour was resistant to virus-specific T-cell therapy — providing proof-of-concept for MDM2 inhibition in this setting.

• Neuroblastoma: Preclinical evaluation using both genetically engineered mouse models (GEMM) and ALK-amplified patient-derived xenografts (PDX) explored navtemadlin-class MDM2 inhibition in combination with the ALK inhibitor lorlatinib. The combination produced complete tumour regression and significantly delayed regrowth, with the observed MDM2/ALK inhibition synergy warranting further clinical evaluation in paediatric neuroblastoma.

• T-Prolymphocytic Leukaemia (T-PLL): Navtemadlin (KRT-232) was assessed through preclinical drug response analyses conducted on samples from 34 T-PLL patients. In one patient cohort, KRT-232 demonstrated high efficacy across all or the majority of samples tested, supporting its potential in this aggressive T-cell malignancy.

• Advanced Solid Tumours and Dedifferentiated Liposarcoma: A first-in-human Phase I study of milademetan — a structurally related MDM2 inhibitor — enrolled 107 patients with advanced solid tumours or lymphomas between July 2013 and August 2018, evaluating extended/continuous and intermittent dosing schedules. The recommended Phase II dose was established as 260 mg once daily on days 1–3 and 15–17 every 28 days. Overall disease control rate was 45.8% with a median PFS of 4.0 months; in the dedifferentiated liposarcoma subgroup (n=53), disease control rate reached 58.5% and median PFS was 7.2 months, prompting a randomised Phase III trial (MANTRA).

• Atherosclerosis: In a non-oncology preclinical context, pharmacological MDM2 inhibition attenuated atherosclerosis development and reversed mitochondrial damage and related inflammation in LDLr mouse models, accompanied by increased RXRβ protein expression in the aorta — highlighting a potential cardiovascular application of MDM2 pathway modulation.

Addressing Key Challenges in Myelofibrosis Treatment Landscape

Myelofibrosis presents a complex therapeutic challenge, with no currently approved treatment capable of modifying the natural history of the disease or eliminating the malignant clone. Unlike Philadelphia chromosome-positive myeloproliferative neoplasms — where BCR-ABL inhibitors have transformed outcomes — the identification of molecular lesions in myelofibrosis has not yet translated into disease-modifying therapy, leaving cure as a persistent unmet clinical need.

• Limited curative options: Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative intervention, but its applicability is restricted by the requirement for a compatible donor and the need for patients to tolerate significant transplant-related toxicity. Achieving a cure will likely require dual targeting of both the malignant stem cell clone and its supportive bone marrow microenvironment.

• Ruxolitinib efficacy ceiling and resistance: Although ruxolitinib improves splenomegaly and disease-related symptoms, many patients lose clinical benefit over time. The agent does not reverse disease progression, resistance emerges frequently, and survival following ruxolitinib failure is poor. The most common failure patterns include loss of spleen or symptom response and the development of clinically significant cytopenias; transformation to accelerated or blast phase, while less frequent, carries an extremely poor prognosis with very limited subsequent treatment options.

• Broader JAK inhibitor pipeline limitations: Ruxolitinib, approved in 2011, long remained the only JAK inhibitor available for myelofibrosis. Numerous other JAK inhibitors have been discontinued due to toxicity, and uncertainty persists around those still in development. Pivotal trial data for momelotinib did not support regulatory approval despite meaningful anemia benefit, toxicity concerns continue to shadow pacritinib, and selective JAK1 inhibition alone is considered unlikely to achieve meaningful efficacy in myelofibrosis.

• Combination therapy complexity: Ruxolitinib-based combinations are emerging as a rational strategy to address the limitations of monotherapy, with a meta-analysis of 19 studies (1,088 patients) identifying 13 distinct regimens — notably ruxolitinib plus selinexor (SVR35: 92%; TSS50: 78%) and ruxolitinib plus BMS-986158 (SVR35: 90%) in JAK inhibitor-naïve patients. However, therapeutic efficacy is significantly influenced by prior JAK inhibitor exposure, and personalized treatment selection remains essential.

• Failed therapeutic approaches: Several agents have demonstrated insufficient efficacy or unacceptable toxicity in clinical evaluation. Bevacizumab (15 mg/kg IV every 21 days) produced no objective responses among 11 treated patients in a phase II trial and was associated with significant toxicity, leading to early study termination. Bortezomib similarly yielded neither remissions nor clinical improvements in 16 patients at the maximum tolerated dose, with thrombocytopenia as the principal toxicity and evidence of worsening disease activity markers.

• Suboptimal anemia management: Danazol, one of the available options for anemia-associated myelofibrosis, demonstrates responses in only approximately 30% of patients overall, with markedly lower efficacy in transfusion-dependent patients (18.5% vs. 43.5% in non-transfusion-dependent patients), a median response duration of only 14 months, and treatment withdrawal due to toxicity in a subset of patients.

Navtemadlin's Position in the MDM2 Inhibitor Landscape for Myelofibrosis

Several MDM2 inhibitors sharing navtemadlin's mechanism of p53-MDM2 interaction blockade have advanced into clinical development across hematologic malignancies and solid tumors. While the literature identifies key agents and trial phases, specific intervention model classifications (e.g., parallel assignment, crossover, single-group) are not consistently reported in the available sources.

Note: Specific intervention models (e.g., single-group assignment, parallel assignment) for these trials were not reported in the available literature. Progression of MDM2 inhibitors as a class has broadly been hampered by acquired drug resistance, dose-dependent toxicity, and limited clinical efficacy.

Ipsen's Strategic Bet on Navtemadlin to Redefine Myelofibrosis Care

The pharmaceutical landscape for myelofibrosis (MF) is on the cusp of a significant transformation, and Ipsen's strategic acquisition of Kartos Therapeutics, centered on the MDM2 inhibitor navtemadlin, underscores this shift. For years, JAK inhibitors like ruxolitinib have been the cornerstone of MF management, offering crucial relief from debilitating symptoms and reducing spleen size. However, studies consistently highlight their limitations: they do not significantly alter the underlying disease progression, many patients develop cytopenias that preclude their use, and outcomes remain poor for those who fail or become refractory to these therapies. This leaves a substantial unmet need for more effective, disease-modifying treatments.

Navtemadlin represents a promising avenue, targeting the MDM2-p53 axis to induce apoptosis in malignant MF cells. This novel mechanism of action positions it as a potential game-changer, not just for symptom management but for truly impacting the natural history of the disease. The drug is being evaluated in two critical Phase 3 trials: BOREAS, for patients with relapsed/refractory MF after JAK inhibitor treatment, and POIESIS, as an add-on therapy for JAK inhibitor-naïve patients with a suboptimal response to ruxolitinib. This dual development strategy is astute, aiming to capture both the second-line and frontline markets where significant patient populations struggle with current options.

However, the path forward is not without its challenges. The MF pipeline is crowded with other innovative non-JAK inhibitor agents, each vying for market share and demonstrating potential disease-modifying effects. The success of navtemadlin hinges critically on the robust outcomes of its ongoing Phase 3 trials, which must demonstrate not only efficacy but also a favorable safety profile, particularly when combined with existing therapies. Ipsen's investment signals a strong belief in navtemadlin's potential to carve out a significant role in this evolving therapeutic space, potentially ushering in an era where combination therapies and personalized approaches become the standard for improving long-term outcomes for MF patients.